Alira Health – a global healthcare consulting and technology firm – announced the securing of up to $100 million in growth debt from premier healthcare and life sciences investor Symbiotic Capital.
This funding round will drive Alira Health’s strategic growth, enhance its innovative technology platforms, and support solutions that empower patients and create value for life sciences companies.
Alira Health established a Chief Operating Officer (COO) role to facilitate this expansion, appointing Andrea Pulvirenti, a seasoned company leader, to oversee operations and scale its global presence.
In January 2023, Alira Health raised $58 million in funding to accelerate Alira Health’s delivery of patient-centric, technology-enabled healthcare solutions. Before that, Alira Health raised $35 million in 2021 and $40 million in 2022 in two rounds led by Creadev.
KEY QUOTES:
“This significant investment from Symbiotic Capital validates our vision for patient-centered healthcare. The funding will enable us to accelerate patient-enabled innovation, scale our integrated solutions, and strengthen the technology platforms that serve both patients and life sciences companies.”
- Gabriele Brambilla, Co-CEO of Alira Health
“We’re excited to partner with Alira Health as they redefine the biopharma and medtech research landscape. Their patient-first approach and integrated solutions are advancing the life sciences ecosystem and improving patient outcomes.”
- Himani Bhalla, Chief Investment Officer and Co-Founder of Symbiotic Capital
